摘要
目的:评价长短效重组人粒细胞刺激因子用于治疗Ⅳ度骨髓抑制的有效性和药物成本效果分析,以促进临床安全、有效、经济的使用该类药品。方法:回顾性分析2015年1月~2016年6月期间首次化疗并导致Ⅳ度骨髓抑制的患者104例,分为两组,其中使用重组人粒细胞集落刺激因子静脉滴注方案的(A组)54例,使用聚乙二醇化重组人粒细胞刺激因子皮下注射方案(B组)50例,比较用药3d后的短期疗效、不良反应评价,计算治疗成本,对两种方案进行药物经济学成本-效果分析。结果:AB两组治疗方案的成本分别为1222.5元、3574元,白细胞减少痊愈率分别为38.9%、34.0%,显效率分别为77.8%、82.0%,差异无统计学意义(P>0.05);不良反应发生率分别为31.5%、14.0%,差异有统计学意义(P<0.05)。结论:考虑药物的有效性、经济性,A组方案是治疗重度骨髓抑制的最佳治疗方案;B组方案有更好的安全性,适合日间化疗的患者。
Objective： To evaluate the efficacy and cost-effectiveness of myelosuppression treated by long and short-acting recombinant human granulocyte-stimulating factors, aiming at using the medicine with safty, effectiveness and economically. Methods： A retrospective analysis was conducted for 104 patients with IV degree of myelosupportression as a result of primary chemotherapy between January 2015 and June 2016. Patients were divided into two groups. 54 of them （Group A） used the recombinant human granulocyte colony-stimulating factor intravenous drip regimen, and 50 of them （group B） used polyethylene glycol recombinant human granulocyte stimulator subcutaneous injection regimen. The short- effective curative effect and adverse reaction evaluation were compared after treating for 3 days. At the same time, the treat- ment cost and cost-effectiveness between the two groups was compared. Results ： It showd that the average costs of the two groups were RMB 1222.5 for group A and RMB 3574 for group B.. The cure rates of leukopenia reduction were 38.9% and 34.0%, the overall cure rates were 77.8% and 82.0% , respectively. No significant difference between the two groups （P 〉 0.05） were found. The incidences of adverse reactions were 31.5% and 14.0% respectively and showd sig-nificant difference. From cost-effectiveness perspective, group A was more economical. Conclusion： Considering the effectiveness and economic usages of medicine, group A regi-men has advantage for severe myelosuppression treatment, while Group B is more secure and is more suitable for daytime chemotherapy.
出处
《肿瘤预防与治疗》
2017年第4期281-284,共4页
Journal of Cancer Control And Treatment
